Infant Bacterial Therapeutics AB

Historical price data

Infant Bacterial Therapeutics AB is dedicated to developing novel, microbiome-based treatments for life-threatening conditions affecting newborns, particularly premature infants. Its core technology involves the administration of specific, naturally occurring bacterial strains to support gut health and prevent devastating diseases. The company's most advanced program, IBP-9414, has completed a pivotal Phase 3 trial (NCT03453177) and is preparing for regulatory submissions, positioning IBT as a leader in neonatal microbiome therapeutics. Its mission is to address the significant unmet medical need in neonatology with safe and effective biological products.

Development of pharmaceutical-grade, live bacterial therapeutics derived from the human infant microbiome, primarily using specific strains of Lactobacillus reuteri to prevent life-threatening conditions in preterm newborns.

Competition includes off-label, non-pharmaceutical probiotic mixtures used in some NICUs and other biotechs developing defined microbiome therapies, though few are neonatology-focused. IBT's differentiation lies in its Phase 3 data, pharmaceutical-grade single-strain product, and specific regulatory strategy for preterm infants.